Integrated Filing — IndAS



General information about company

Scrip Code 531349
NSE Symbol PANACEABIO
MSEI Symbol NOTLISTED
ISIN INE922B01023
Name of company PANACEA BIOTEC LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 13-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Vaccines
Start date and time of board meeting 13-08-2026   16:46:00
End date and time of board meeting 13-08-2026   17:27:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 13,471.00 13,471.00
Other income 606.00 606.00
Total income 14,077.00 14,077.00
2 Expenses
(a) Cost of materials consumed 5,379.00 5,379.00
(b) Purchases of stock-in-trade 20.00 20.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 2,401.00 2,401.00
(d) Employee benefit expense 2,283.00 2,283.00
(e) Finance costs 689.00 689.00
(f) Depreciation, depletion and amortisation expense 447.00 447.00
(f) Other Expenses
1 Other Expenses 2,658.00 2,658.00
Total other expenses 2,658.00 2,658.00
Total expenses 13,877.00 13,877.00
3 Total profit before exceptional items and tax 200.00 200.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 200.00 200.00
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 61.00 61.00
9 Total tax expenses 61.00 61.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 139.00 139.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 139.00 139.00
17 Other comprehensive income net of taxes 28.00 28.00
18 Total Comprehensive Income for the period 167.00 167.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 613.00 613.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.23 0.23
Diluted earnings (loss) per share from continuing operations 0.23 0.23
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.23 0.23
Diluted earnings (loss) per share from continuing and discontinued operations 0.23 0.23
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026, and have been reviewed by the statutory auditor of the Company. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The consolidated financial results of the Company have been prepared by consolidating the unaudited financial results of the Company and its material subsidiary Panacea Biotec Pharma Limited (“PBPL”) for the respective periods, with the unaudited (management reviewed and approved) financial results of its wholly owned subsidiaries (“WOS”) and the enterprises over which the Company exercises control (“Enterprises”) (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as “the Group”) for the respective periods: (i) WOS: Meyten Realtech Private Limited, Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and (ii) Enterprises*: PanEra Biotec Private Limited and Adveta Power Private Limited. *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 4. For the quarter ended June 30, 2026, the Company and Group has earned profit (including other comprehensive income) of Rs.167 lakh and Rs.258 lakh (quarter ended June 30, 2025: loss of Rs.668 lakh and profit of Rs.394 lakh), respectively. As on June 30, 2026, the retained earnings of the Company are negative to the extent of Rs.21,615 lakh (June 30, 2025: Rs.19,577 lakh). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group as on June 30, 2026 are positive. The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers, resulting into higher revenues and profits during the current quarter. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. 5. During the quarter ended June 30, 2026, the Group has recognised exceptional income of Rs.274 lakh (quarter ended June 30, 2025: Rs.1,132 lakh) in the consolidated statement of profit and loss, which includes: (i) income of Rs. Nil (quarter ended June 30, 2025: Rs.858 lakh), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL; and (ii) income of Rs.274 Lakh (quarter ended June 30, 2025: Rs.274 lakh), out of the remaining deferred consideration of Rs.1,019 Lakh as at March 31, 2026, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.745 lakh (June 30, 2025: Rs.1,837 lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 6. Amounts for the quarter ended March 31, 2026 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the financial year ended March 31, 2026, which had been subjected only to limited review. 7. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter ended June 30, 2026. 8. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 9. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. 10. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 11. The above results are also available on the Company’s website https://www.panaceabiotec.com.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified 38.00 38.00
Total Amount of items that will not be reclassified to profit and loss 38.00
2 Income tax relating to items that will not be reclassified to profit or loss 10.00 10.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified 0.00 0.00
Total Amount of items that will be reclassified to profit and loss 0.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 28.00 28.00